Effects of rosuvastatin on blood lipid, inflammatory mediators,endothelial function in patients with coronary heart disease and hyperlipidemia

DIAO Yuanbin; QIAN Zhiping; LUO Jiangxiu; XU Liyan; TAN Yuyao

doi:10.3969/j.issn.1671-6450.2017.08.003

Abstract：Objective To investigate the clinical efficacy and effects of rosuvastatin on blood lipid,inflammatory mediators,liver and kidney function in patients with coronary heart disease and hyperlipidemia.Methods Ninety-eight cases of patients with coronary heart disease and hyperlipidemia were selected,who were treated in hospital from February 2015 to February 2017,and they were divided into the observation group(49 cases)and control group(49 cases).The patients of two groups were all treated with antihypertensive,diabetic basic treatment.The patients of observation group were treated with rosuvastatin(taken after dinner,1 tablet/time,1 time/d).The patients of control group were treated with simvastatin tablets(taken after dinner,1 tablet/time,1 time/d).The patients of two groups were all treated for 12 weeks.The clinical efficacy,the incidence of adverse reactions and changes of the levels of blood lipid(TC、TG、HDL-C、LDL-C),inflammatory mediators(CRP,APN,NO,ET-1),liver and kidney function(ALT,CK,SCr and BUN)of two groups were compared.Results After the appropriate treatment for 12 weeks,the patients of the observation group got a total effective rate of 93.8％,which was significantly better than the 79.6％of the control group(x2=4.346,P=0.037);The levels of TG,TC,LDL-C,Apo Al,Apo B of the observation group were significantly lower than those of the control group(t=4.124,t=11.121,t=7.126,t=2.005,t=1.898,P=0.000,P=0.000,P=0.000,P=0.024,P=0.030,P=0.019),the levels of HDL-C of the observation group were significantly higher than those of the control group(t=2.102,P=0.000);CRP、ET-1 levels of observation group were lower than control group,while APN,NO levels were higher than control group(t=1.791,17.167,33.295,16.324,P=0.038,P=0.000,P=0.000,P=0.000).There were no significant difference in ALT,CK,SCr and BUN between the two groups(t=0.070,t=0.319,t=0.629,t=0.098,P=0.472,P=0.375,P=0.265,P=0.461);There were vomiting,diarrhea,rash,myalgia,elevated ALT and other adverse reactions occurred in both two groups,and the incidence of observation group were significantly lower than that in the control group(x2=3.971,x2=4.382,x2=5.869,x2=4.186,P=0.046,P=0.036,P=0.015,P=0.041).Conclusion Treating patients with coronary heart disease and hyperlipidemia,rosuvastatin can improve clinical efficacy,reduce blood lipids,reduce inflammatory response,and its impact on liver and kidney function is small,with high safety,which makes it worthy of clinical promotion.